Company / Cash & Equivalents
Savara Inc Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$15.1M
FY2024
5-year range
$15.1M / $52.1M
FY2020-FY2024
Trend
-43.1%
vs FY2023
Sector context
#201 of 207
Health Care
What the data says
Among 207 Health Care companies, Savara Inc is in the bottom 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $13M in FY2016 to $52M in FY2022.
Based on SEC 10-K filings.
$15M in FY2024 with a 5-year CAGR of -21.2%.
Declined from $52M to $15M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.7%
- 5-Year CAGR
- -21.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 207This company $15.1M Sector average $669.5M
▼
-97.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -21.2%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 43.1% year-over-year.
- Ranks #201 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.1M | -43.1% |
| FY2023 | $26.6M | -49.0% |
| FY2022 | $52.1M | +53.2% |
| FY2021 | $34.0M | +48.7% |
| FY2020 | $22.9M | -54.1% |
| FY2019 | $49.8M | +104.9% |
| FY2018 | $24.3M | +9.9% |
| FY2017 | $22.1M | +65.4% |
| FY2016 | $13.4M | -19.8% |
| FY2015 | $16.7M | +31.5% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026